{"gene":"CES1","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1991,"finding":"CES1 (carboxylesterase 1) is expressed as a serine esterase in human alveolar macrophages and monocytes, where it is released into bronchoalveolar lavage fluid associated with surfactant; it is virtually identical to liver microsomal carboxylesterase, establishing CES1 as both a hepatic and macrophage enzyme with detoxification function.","method":"Protein purification, [3H]DFP labeling, NH2-terminal sequencing, PCR cloning from macrophage cDNA library, Northern blot","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal methods: purification, active-site labeling, sequencing, cloning, expression confirmation","pmids":["1918003"],"is_preprint":false},{"year":1993,"finding":"CES1 (hCE) encodes a 568-amino-acid serine hydrolase with an 18-aa signal peptide; baculovirus-expressed hCE hydrolyzes aromatic and aliphatic esters but not amides or fatty acyl-CoA esters; N-glycosylation is essential for maximal catalytic activity, as tunicamycin inhibition substantially reduces activity; two highly similar variants (hCE and hCEv) were identified as distinct gene family members.","method":"cDNA cloning, baculovirus expression in Sf9 cells, enzymatic assays, tunicamycin inhibition, somatic cell hybrid chromosome mapping","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted enzyme activity with mutagenesis-equivalent variant comparison and glycosylation inhibition","pmids":["8218228"],"is_preprint":false},{"year":1997,"finding":"Purified human liver CES1 (hCE-1) catalyzes hydrolysis of cocaine to benzoylecgonine, deacetylation of heroin to 6-acetylmorphine, and ethanol-dependent transesterification of cocaine to cocaethylene; binding is stereoselective for (R)-(-)-cocaine, and the methyl ester, benzoyl, and N-methyl groups of cocaine are critical for binding affinity.","method":"Purified enzyme kinetic assays, competitive inhibition with 4-methylumbelliferyl acetate, stereoisomer comparison","journal":"Drug metabolism and disposition","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with purified enzyme, multiple substrates and stereoisomers","pmids":["9311626"],"is_preprint":false},{"year":2000,"finding":"CES1 expressed in human macrophages functions as a cholesteryl ester hydrolase (CEH); overexpression in COS cells yielded >20-fold increased CEH activity; overexpression in CHO-K1 cells impaired LDL receptor mRNA upregulation under cholesterol-deficient conditions, placing CES1 in the intracellular cholesteryl ester metabolism pathway.","method":"RT-PCR, cDNA cloning, transient transfection in COS-1/COS-7/CHO-K1 cells, enzymatic activity assay, Northern blot","journal":"Physiological genomics","confidence":"High","confidence_rationale":"Tier 1-2 — reconstituted activity in transfected cells with defined functional (LDL receptor) phenotypic readout","pmids":["11015575"],"is_preprint":false},{"year":2003,"finding":"Crystal structures of human CES1 (hCE1) in complex with the cocaine analog homatropine and heroin analog naloxone reveal that the active site contains both a specific and a promiscuous compartment enabling metabolism of structurally distinct chemicals; a separate surface ligand-binding site regulates the trimer-hexamer equilibrium and allows each monomer to bind two narcotic molecules simultaneously.","method":"X-ray crystallography of hCE1 glycoprotein complexes","journal":"Nature structural biology","confidence":"High","confidence_rationale":"Tier 1 — crystal structures with functional interpretation, multiple complexes","pmids":["12679808"],"is_preprint":false},{"year":2003,"finding":"Crystal structure of hCE1 with tacrine (2.4 Å) shows tacrine binds in multiple orientations within the catalytic gorge, in contrast to acetylcholinesterase; this promiscuity is structurally explained by the larger, flexible active-site architecture of hCE1; tacrine derivatives were identified as low-micromolar CES1 inhibitors.","method":"X-ray crystallography, inhibitor screening assays","journal":"Chemistry & biology","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure with functional inhibitor validation","pmids":["12725862"],"is_preprint":false},{"year":2004,"finding":"CES1A1 (along with CES2 and CES3) hydrolyzes irinotecan and its oxidative metabolites NPC and APC to the active metabolite SN-38; the relative catalytic efficiency for CPT-11 hydrolysis is CES2 > CES1A1 >> CES3.","method":"Purified recombinant enzyme kinetic assays","journal":"Drug metabolism and disposition","confidence":"High","confidence_rationale":"Tier 1 — purified recombinant enzymes with full kinetic characterization","pmids":["15100172"],"is_preprint":false},{"year":2006,"finding":"Crystal structures of hCE1 with CoA, palmitate, cholate, and taurocholate reveal three ligand-binding sites (active site plus two additional sites), all exhibiting non-specific binding; this multisite promiscuity structurally explains CES1's ability to perform cholesterol ester hydrolysis, fatty acyl-CoA hydrolysis, acyl-CoA:cholesterol acyltransfer, and fatty acyl ethyl ester synthesis depending on cellular context.","method":"X-ray crystallography of four hCE1 complexes with endogenous substrates/analogs","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 — four crystal structures establishing structural basis of multisite catalytic promiscuity","pmids":["16962139"],"is_preprint":false},{"year":2008,"finding":"Two CES1 coding mutations, p.Gly143Glu (exon 4) and p.Asp260fs (exon 6 frameshift/premature stop), cause complete loss of hydrolytic activity toward methylphenidate; p.Gly143Glu retains only 21.4% catalytic efficiency (Vmax/Km) and p.Asp260fs retains 0.6% relative to wild-type using p-nitrophenyl acetate; minor allele frequency of p.Gly143Glu is 3.7%/4.3%/2.0%/0% in white/black/Hispanic/Asian populations.","method":"DNA sequencing, in vitro functional expression, kinetic assays with methylphenidate and p-nitrophenyl acetate","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzyme activity assays with two distinct substrates, population frequency determination","pmids":["18485328"],"is_preprint":false},{"year":2008,"finding":"Human CES1 (HCE1) is expressed predominantly in liver and shows age-dependent ontogeny: fetal liver has lowest expression (~10-fold lower than adult), child liver is intermediate; CES1 selectively hydrolyzes oseltamivir over CES2, and adult microsomes are ~4× more active than child and ~10× more active than fetal microsomes; large inter-individual variability (up to 100-fold in protein) exists within the same age group.","method":"RT-qPCR, Western immunoblotting across 104 liver samples (fetal, child, adult), hydrolytic activity assays","journal":"Biochemical pharmacology","confidence":"High","confidence_rationale":"Tier 2 — large sample proteomics with correlated functional activity, multiple substrates","pmids":["18983829"],"is_preprint":false},{"year":2009,"finding":"Mouse esterase-x/Ces1 (Es-x/Ces1), stably expressed in McArdle-RH7777 hepatocytes, reduces triacylglycerol (TG) accumulation by redirecting exogenous fatty acids toward beta-oxidation rather than TG synthesis, as evidenced by increased acid-soluble metabolites; this TG-lowering effect persisted with esterase inhibitor E600, indicating the mechanism is primarily reduction of fatty acid partitioning into TG rather than increased TG turnover; Es-x expression did not alter VLDL-TG or apolipoprotein B secretion.","method":"Stable transfection of McArdle-RH7777 cells, TG quantification, acid-soluble metabolite measurement, E600 inhibitor experiment, glycerol supplementation","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 2 — gain-of-function in defined cell line with pharmacological inhibitor dissection and multiple metabolic readouts","pmids":["19651238"],"is_preprint":false},{"year":2012,"finding":"CES1 is the primary enzyme responsible for hydrolytic inactivation of clopidogrel and its intermediate 2-oxo-clopidogrel in human liver S9 fractions; inhibition of CES1 by bis(4-nitrophenyl) phosphate significantly increased concentrations of clopidogrel active metabolite; CES1 variants G143E and D260fs have completely impaired catalytic activity toward clopidogrel and 2-oxo-clopidogrel, whereas variants G18V, S82L, and A269S show no significant effect.","method":"Human liver S9 fraction incubations, CES1 inhibitor experiments, transfected cell line S9 fractions, LC-MS/MS metabolite quantification","journal":"The Journal of pharmacology and experimental therapeutics","confidence":"High","confidence_rationale":"Tier 1-2 — inhibitor dissection plus variant functional characterization with defined substrate metabolite profiles","pmids":["23275066"],"is_preprint":false},{"year":2013,"finding":"The CES1 G143E variant carriers show significantly increased clopidogrel active metabolite levels and better clopidogrel response (reduced ADP-stimulated platelet aggregation) compared with non-carriers, confirming that CES1-mediated hydrolysis constitutes the primary inactivation route of clopidogrel in vivo.","method":"Clinical pharmacogenomics study (PAPI study, n=566 + 350 CHD patients), active metabolite measurement, platelet aggregation assay","journal":"Pharmacogenetics and genomics","confidence":"High","confidence_rationale":"Tier 2 — clinical validation of in vitro mechanistic finding, two independent cohorts","pmids":["23111421"],"is_preprint":false},{"year":2013,"finding":"Recombinant human CES1 efficiently hydrolyzes enalapril, ramipril, and trandolapril (but not CES2), establishing CES1 as the primary activating enzyme for these ACE inhibitor prodrugs; enalapril shows substrate inhibition kinetics while ramipril and trandolapril follow Michaelis-Menten kinetics; isradipine and tacrolimus are identified as novel CES1 inhibitors.","method":"Recombinant enzyme assays, Michaelis-Menten/substrate inhibition kinetic modeling, inhibitor screening with human liver microsomes","journal":"Drug metabolism and disposition","confidence":"High","confidence_rationale":"Tier 1 — purified recombinant enzyme kinetics with multiple substrates and inhibitor identification","pmids":["24141856"],"is_preprint":false},{"year":2015,"finding":"CES1 selectively activates ACE inhibitor prodrugs enalapril, ramipril, perindopril, moexipril, and fosinopril in human liver (not intestine or kidney); the G143E variant is a loss-of-function variant reducing enalapril activation to ~one-third of wild-type in human liver samples carrying the 143G/E genotype; neither CES1/CES1VAR nor CES1P1/CES1P1VAR genotypes/diplotypes affected hepatic CES1 expression or activity in normal liver samples.","method":"Human liver/intestine/kidney S9 fraction incubations, CES1 inhibitor (BNPP), recombinant transfected cell lines, 102 normal human liver samples","journal":"The pharmacogenomics journal","confidence":"High","confidence_rationale":"Tier 1-2 — organ selectivity established with inhibitor, genetic variant functional characterization in human liver samples","pmids":["26076923"],"is_preprint":false},{"year":2015,"finding":"Fluoxetine decreases CES1 expression and hydrolytic activity in HepG2 cells by decreasing pregnane X receptor (PXR) expression and increasing DEC1; PXR overexpression attenuated and PXR knockdown abolished CES1 decreases; DEC1 knockdown increased PXR and restored CES1, establishing a FLX→DEC1↑/PXR↓→CES1↓ transcriptional regulatory axis.","method":"HepG2 cell transfection (overexpression and siRNA knockdown), RT-PCR, Western blot, enzymatic activity assay","journal":"Xenobiotica","confidence":"High","confidence_rationale":"Tier 2 — bidirectional genetic manipulation (OE + KD) establishing epistatic transcriptional pathway","pmids":["26340669"],"is_preprint":false},{"year":2016,"finding":"Sacubitril is selectively activated (hydrolyzed) by CES1 in human liver S9 fractions but not by CES2 or in intestine/kidney/plasma; the G143E variant is a loss-of-function variant for sacubitril activation; human livers with G143E genotype show significantly impaired sacubitril activation.","method":"Incubation with human tissue S9 fractions, CES1-selective inhibitor BNPP, recombinant CES1 and CES2, transfected cell lines, human liver samples with G143E genotyping","journal":"Drug metabolism and disposition","confidence":"High","confidence_rationale":"Tier 1-2 — multiple complementary approaches establishing organ/enzyme selectivity and loss-of-function variant","pmids":["26817948"],"is_preprint":false},{"year":2016,"finding":"The CES1VAR genomic translocation (replacing 5'UTR, exon 1, and part of intron 1 with CES1P1 pseudogene sequence, minor allele frequency 17%) reduces CES1 mRNA by ~2.6-fold and allelic mRNA by ~1.35-fold; however, CES1VAR did not detectably alter CES1 protein expression or metabolizing activity toward enalapril, clopidogrel, or methylphenidate in liver.","method":"Sanger and Ion Torrent sequencing, allelic mRNA analysis (SNaPshot), quantitative targeted proteomics, luciferase reporter assays in HepG2","journal":"Pharmacogenetics and genomics","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including proteomics and reporter assays in liver tissue","pmids":["26871237"],"is_preprint":false},{"year":2016,"finding":"CES1 and CES2 protein abundance in human liver microsomes increases approximately 5-fold and 3-fold from neonates to adults, respectively; oseltamivir carboxylase activity correlates with CES1 protein abundance across pediatric and adult liver microsomes, validating the ontogeny function for PBPK modeling.","method":"LC-MS/MS proteomics with purified protein standards as calibrators and heavy-labeled peptide internal standards in 171 liver samples","journal":"Drug metabolism and disposition","confidence":"High","confidence_rationale":"Tier 2 — quantitative proteomics with functional correlation across large sample set","pmids":["27895113"],"is_preprint":false},{"year":2018,"finding":"The CES1 G143E variant (p.Gly143Glu) reduces lipolytic activity to ~20% of wild-type; humanized mice expressing CES1G143E on a Ces1-null background fed a high-fat diet show reduced liver and plasma triacylglycerol levels; the hypolipidemic mechanism involves decreased VLDL secretion, decreased hepatic lipogenic gene expression, and increased fatty acid oxidation (elevated plasma ketone bodies and hepatic mitochondrial electron transport chain protein abundance).","method":"Humanized mouse model (liver-specific CES1WT, CES1G143E, CES1S221A expression on Ces1-/- background), high-fat diet feeding, TG/cholesterol measurements, lipogenic gene expression, ketone body assay, mitochondrial protein quantification","journal":"Biochimica et biophysica acta. Molecular and cell biology of lipids","confidence":"High","confidence_rationale":"Tier 1-2 — humanized mouse model with catalytic-dead control, multiple mechanistic readouts","pmids":["29631096"],"is_preprint":false},{"year":2017,"finding":"Global inactivation of Ces1/Ces1g in Ldlr-/- mice protects against atherosclerosis by inhibiting intestinal cholesterol and fat absorption (including reduced Niemann-Pick C1-like 1 expression), increasing macrophage cholesterol efflux (via ABCA1 and ABCG1 induction), promoting M2 macrophage polarization, and inducing hepatic cholesterol 7α-hydroxylase and sterol 12α-hydroxylase; paradoxically, hepatic-specific Ces1/Ces1g knockdown in Apoe-/- mice exacerbated atherogenesis.","method":"Ces1g-/- Ldlr-/- double knockout mice, Western diet feeding, atherosclerotic lesion quantification, intestinal cholesterol absorption assay, macrophage cholesterol efflux assay, gene expression analysis","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout with multiple mechanistic readouts and organ-specific knockdown comparison","pmids":["29259301"],"is_preprint":false},{"year":2019,"finding":"Vitamin E reverses NAFLD-associated lipid accumulation in fructose-treated mice via upregulation of Nrf2 and CES1; the Nrf2 inhibitor ML385 abolished the protective effects of vitamin E on lipid metabolism, establishing a Nrf2→CES1 signaling axis in hepatic lipid homeostasis.","method":"NAFLD mouse model (fructose feeding), vitamin E treatment, Nrf2 inhibitor (ML385), histopathology, lipid assays, in vitro L02 cell experiments","journal":"Digestive diseases and sciences","confidence":"Medium","confidence_rationale":"Tier 2-3 — pharmacological inhibitor establishes pathway but mechanistic link between Nrf2 and CES1 relies on inhibitor alone","pmids":["31076985"],"is_preprint":false},{"year":2019,"finding":"CES1 is the most abundant drug-metabolizing enzyme in human liver (~1% of entire liver proteome), responsible for 80-95% of total hepatic hydrolytic activity; alcohol is identified as a potent CES1 inhibitor that can alter therapeutic outcomes of CES1 substrate medications.","method":"Proteomic quantification studies (reviewed), inhibitor characterization studies (reviewed)","journal":"Drug metabolism and disposition","confidence":"Medium","confidence_rationale":"Tier 2 — review synthesizing proteomic abundance data and inhibition studies, single review paper","pmids":["31871135"],"is_preprint":false},{"year":2020,"finding":"CES1 in human monocytic THP-1 cells hydrolyzes prostaglandin D2-glyceryl ester (PGD2-G), accounting for ~50% of its hydrolytic metabolism; CES1 knockdown or pharmacological inhibition (CPO, WWL113, WWL229) stabilizes PGD2-G, augmenting its anti-inflammatory effects (reduced IL-6, TNFα) upon LPS stimulation; PGD2-G (and/or downstream metabolites) activates PPARγ, altering alternative macrophage activation; inhibitor potency rank order: CPO > WWL113 > WWL229.","method":"THP-1 cell CES1 knockdown (siRNA), CES1 inhibitor dose-response, LC-MS/MS metabolite quantification, cytokine ELISA, PPARγ activation assay","journal":"ACS omega","confidence":"High","confidence_rationale":"Tier 2 — genetic KD plus pharmacological inhibition with orthogonal readouts establishing CES1 as PGD2-G hydrolase in macrophages","pmids":["33225149"],"is_preprint":false},{"year":2021,"finding":"Melatonin treatment restores CES1 expression in prostate cancer cells via epigenetic modification; restored CES1 expression reduces lipid droplet accumulation, induces ER stress-mediated apoptosis, and reduces intratumoral androgen synthesis; Ces1-knockout mice show increased PCa tumor growth, confirming CES1's tumor-suppressive role via lipid metabolism regulation.","method":"Animal CRPC models, PCa cell lines, Ces1-/- mouse model, lipid droplet quantification, apoptosis assays, androgen synthesis measurement, epigenetic assays","journal":"Clinical and translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 — knockout mouse and cell line experiments with multiple readouts; epigenetic mechanism not fully defined","pmids":["34185414"],"is_preprint":false},{"year":2021,"finding":"CES1 G143E heterozygous carriers show 30.9% lower enalaprilat Cmax and 27.5% lower enalaprilat AUC0-∞ at steady state compared to non-carriers; carriers also showed no statistically significant blood pressure reduction vs ~12.4% reduction in non-carriers, directly linking CES1 loss-of-function to impaired prodrug activation and pharmacodynamic effect in vivo.","method":"Prospective multi-dose PK/PD clinical study, LC-MS/MS quantification, blood pressure monitoring","journal":"British journal of clinical pharmacology","confidence":"High","confidence_rationale":"Tier 2 — prospective clinical trial with PK and PD endpoints linking genetic variant to functional consequence","pmids":["33963573"],"is_preprint":false},{"year":2022,"finding":"TMAO (trimethylamine N-oxide) increases Ces1 protein expression and activity in mouse liver and HepG2 cells via a NOX-dependent ROS/Nrf2/CES1 pathway, leading to increased clopidogrel hydrolysis (inactivation) and impaired platelet response; co-administration of TMAO-synthesis inhibitor (3,3-dimethyl-1-butanol), antioxidant (N-acetyl-L-cysteine), or Nrf2 inhibitor (ML385) reversed these effects.","method":"Mouse dietary TMAO/choline feeding, pharmacological pathway dissection (FMO inhibitor, antioxidant, Nrf2 inhibitor), HepG2 cell treatment, Ces1 protein/activity measurement, clopidogrel metabolite LC-MS/MS, platelet aggregation assay","journal":"Journal of thrombosis and haemostasis","confidence":"High","confidence_rationale":"Tier 2 — multiple pharmacological inhibitors at different pathway nodes in both in vivo and in vitro models","pmids":["36695375"],"is_preprint":false},{"year":2023,"finding":"CES1 inhibition (pharmacological or siRNA) in hepatocellular carcinoma cells alters lipid profiles by reducing polyunsaturated fatty acids (PUFAs), which activates PPARα/γ; loss of PPARα/γ activation downregulates the target gene SCD (involved in chemoresistance); the CES1-PPARα/γ-SCD axis sensitizes HCC cells to cisplatin, and co-administration of cisplatin with CES1 inhibition slows xenograft tumor growth.","method":"Pharmacological CES1 inhibition, siRNA knockdown, lipidomic analysis, PPARα/γ pathway analysis, SCD expression measurement, cisplatin sensitivity assays, xenograft mouse model","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 — lipidomics plus genetic and pharmacological inhibition establishing mechanistic pathway with in vivo validation","pmids":["36472914"],"is_preprint":false},{"year":2023,"finding":"G9a (Ehmt2-encoded histone methyltransferase) suppresses transcription of Ces1 in renal tubules; G9a and farnesoid X receptor (FXR) competitively bind to the same promoter regions of Ces1; tubular-specific G9a knockout (Ehmt2Ksp) or G9a inhibition derepresses Ces1, reducing lipid accumulation and alleviating AKI; pharmacological Ces1 inhibition reverses the AKI-protective effect of Ehmt2Ksp mice, establishing a G9a/FXR-Ces1 axis controlling renal lipid homeostasis.","method":"Renal tubular-specific G9a knockout mice, pharmacological G9a inhibition, Ces1 pharmacological inhibition, chromatin binding assays (G9a vs FXR competition at Ces1 promoter), lipid staining, AKI model (I/R and cisplatin), atorvastatin and FXR agonist treatment","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 1-2 — conditional knockout with promoter competition mechanism, multiple genetic and pharmacological epistasis experiments","pmids":["37042626"],"is_preprint":false},{"year":2024,"finding":"Nicotine activates CHRNA5 in head and neck squamous cell carcinoma cells, which physically interacts with CES1 (confirmed by co-immunoprecipitation and molecular docking); CHRNA5 activation via the MEK/ERK pathway upregulates CES1 expression; CHRNA5 knockdown reduces CES1 mRNA and protein levels, an effect reversed by nicotine exposure.","method":"Co-immunoprecipitation, molecular docking, immunofluorescence, CHRNA5 knockdown/overexpression, Western blot for p-MEK/MEK, p-ERK/ERK and CES1, nude mouse tumor formation assay","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP establishes CHRNA5-CES1 interaction; MEK/ERK regulation supported by knockdown but single lab","pmids":["39472448"],"is_preprint":false},{"year":2018,"finding":"CES1 in human lungs is present predominantly in the microsomal fraction with 30-50-fold higher Vmax for pNPA (CES1 marker substrate) compared to FD (CES2 marker); CES1 and CES2 show 2.5-5-fold and 8-15-fold inter-individual variation in lung hydrolytic activity, respectively, demonstrating CES1 as the dominant esterase in human lung tissue.","method":"Cytosol and microsomal fractionation of 20 human lung samples, kinetic assays (Vmax, Km), selective inhibitor studies (loperamide for CES2, BNPP, PMSF)","journal":"Biochemical pharmacology","confidence":"High","confidence_rationale":"Tier 2 — kinetic characterization with selective inhibitors across multiple tissue samples establishing CES1 as dominant lung esterase","pmids":["29407485"],"is_preprint":false},{"year":2018,"finding":"MiR-155 overexpression in THP-1 macrophages upregulates CES1 (CEH) mRNA and protein in a dose- and time-dependent manner; miR-155-mediated CEH induction reduces intracellular cholesteryl ester accumulation and foam cell formation; siRNA knockdown of CEH reverses miR-155's anti-foam cell effect; Tim-3 overexpression attenuates miR-155-mediated CEH induction, placing Tim-3 upstream of the miR-155/CES1 axis.","method":"miR-155 mimic transfection, siCEH knockdown, Tim-3 overexpression in THP-1 macrophages, cholesterol efflux assay, lipid accumulation quantification, RT-PCR and Western blot","journal":"Biomedicine & pharmacotherapy","confidence":"Medium","confidence_rationale":"Tier 2-3 — gain and loss of function with functional readout; regulatory mechanism partially defined","pmids":["29803178"],"is_preprint":false}],"current_model":"Human CES1 is a serine hydrolase primarily localized in hepatic microsomes and macrophages where it catalyzes the hydrolysis, transesterification, and activation of diverse substrates including drugs (clopidogrel, methylphenidate, ACE inhibitor prodrugs, sacubitril), narcotics (cocaine, heroin), and endogenous lipids (cholesteryl esters, prostaglandin glyceryl esters, triacylglycerols); its crystal structures reveal a promiscuous active site with multiple ligand-binding sites; N-glycosylation is required for maximal activity; the loss-of-function variant G143E abolishes or severely impairs activity toward all tested substrates; CES1 expression is transcriptionally regulated by PXR/DEC1, Nrf2, G9a/FXR, and miR-155/Tim-3 axes; and through lipid substrate metabolism, CES1 controls hepatic VLDL secretion, macrophage cholesterol efflux, renal lipid homeostasis, and tumor lipid signaling via PPARα/γ-SCD."},"narrative":{"teleology":[],"mechanism_profile":{"molecular_activity":[],"localization":[],"pathway":[],"complexes":[],"partners":[],"other_free_text":[]},"mechanistic_narrative":"Insufficient on-target evidence to synthesize a narrative — discovery timeline does not match the canonical CES1 protein."},"prefetch_data":{"uniprot":{"accession":"P23141","full_name":"Liver carboxylesterase 1","aliases":["Acyl-coenzyme A:cholesterol acyltransferase","ACAT","Brain carboxylesterase hBr1","Carboxylesterase 1","CE-1","hCE-1","Cholesteryl ester hydrolase","CEH","Cocaine carboxylesterase","Egasyn","HMSE","Methylumbelliferyl-acetate deacetylase 1","Monocyte/macrophage serine esterase","Retinyl ester hydrolase","REH","Serine esterase 1","Triacylglycerol hydrolase","TGH"],"length_aa":567,"mass_kda":62.5,"function":"Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs (PubMed:18762277, PubMed:7980644, PubMed:9169443, PubMed:9490062). Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl-CoA ester (PubMed:18762277, PubMed:7980644, PubMed:9169443, PubMed:9490062). Hydrolyzes the methyl ester group of cocaine to form benzoylecgonine (PubMed:7980644). Catalyzes the transesterification of cocaine to form cocaethylene (PubMed:7980644). Displays fatty acid ethyl ester synthase activity, catalyzing the ethyl esterification of oleic acid to ethyloleate (PubMed:7980644). Converts monoacylglycerides to free fatty acids and glycerol. Hydrolyzes of 2-arachidonoylglycerol and prostaglandins (PubMed:21049984). Hydrolyzes cellular cholesteryl esters to free cholesterols and promotes reverse cholesterol transport (RCT) by facilitating both the initial and final steps in the process (PubMed:11015575, PubMed:16024911, PubMed:16971496, PubMed:18762277). First of all, allows free cholesterol efflux from macrophages to extracellular cholesterol acceptors and secondly, releases free cholesterol from lipoprotein-delivered cholesteryl esters in the liver for bile acid synthesis or direct secretion into the bile (PubMed:16971496, PubMed:18599737, PubMed:18762277)","subcellular_location":"Endoplasmic reticulum lumen; Cytoplasm; Lipid droplet","url":"https://www.uniprot.org/uniprotkb/P23141/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CES1","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CES1","total_profiled":1310},"omim":[{"mim_id":"618678","title":"CARBOXYLESTERASE 5A; CES5A","url":"https://www.omim.org/entry/618678"},{"mim_id":"618057","title":"DRUG METABOLISM, ALTERED, CES1-RELATED","url":"https://www.omim.org/entry/618057"},{"mim_id":"605279","title":"CARBOXYLESTERASE 3; CES3","url":"https://www.omim.org/entry/605279"},{"mim_id":"605278","title":"CARBOXYLESTERASE 2; CES2","url":"https://www.omim.org/entry/605278"},{"mim_id":"602150","title":"SNAIL FAMILY TRANSCRIPTIONAL REPRESSOR 2; SNAI2","url":"https://www.omim.org/entry/602150"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Endoplasmic reticulum","reliability":"Supported"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":2354.1}],"url":"https://www.proteinatlas.org/search/CES1"},"hgnc":{"alias_symbol":["HMSE","CES2","HMSE1","SES1","CEH","CES1A1","CES1A2"],"prev_symbol":[]},"alphafold":{"accession":"P02795","domains":[{"cath_id":"4.10.10.10","chopping":"1-30","consensus_level":"medium","plddt":77.718,"start":1,"end":30},{"cath_id":"-","chopping":"33-61","consensus_level":"medium","plddt":84.1845,"start":33,"end":61}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P02795","model_url":"https://alphafold.ebi.ac.uk/files/AF-P02795-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P02795-F1-predicted_aligned_error_v6.png","plddt_mean":80.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CES1","jax_strain_url":"https://www.jax.org/strain/search?query=CES1"},"sequence":{"accession":"P02795","fasta_url":"https://rest.uniprot.org/uniprotkb/P02795.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P02795/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P02795"}},"corpus_meta":[{"pmid":"11493519","id":"PMC_11493519","title":"A regulatory cascade of three homeobox genes, ceh-10, ttx-3 and ceh-23, controls cell fate specification of a defined interneuron class in C. elegans.","date":"2001","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/11493519","citation_count":248,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18485328","id":"PMC_18485328","title":"Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis.","date":"2008","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18485328","citation_count":188,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8700229","id":"PMC_8700229","title":"Transcriptional regulator of programmed cell death encoded by Caenorhabditis elegans gene ces-2.","date":"1996","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8700229","citation_count":141,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15100172","id":"PMC_15100172","title":"Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.","date":"2004","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/15100172","citation_count":105,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10518212","id":"PMC_10518212","title":"The C. elegans cell death specification gene ces-1 encodes a snail family zinc finger protein.","date":"1999","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/10518212","citation_count":102,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19508181","id":"PMC_19508181","title":"Human carboxylesterases: an update on CES1, CES2 and CES3.","date":"2009","source":"Protein and peptide letters","url":"https://pubmed.ncbi.nlm.nih.gov/19508181","citation_count":100,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12874127","id":"PMC_12874127","title":"The Snail-like CES-1 protein of C. elegans can block the expression of the BH3-only cell-death activator gene egl-1 by antagonizing the function of bHLH proteins.","date":"2003","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12874127","citation_count":99,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27895113","id":"PMC_27895113","title":"Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants.","date":"2016","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/27895113","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24988246","id":"PMC_24988246","title":"The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect.","date":"2014","source":"Drug metabolism and drug interactions","url":"https://pubmed.ncbi.nlm.nih.gov/24988246","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9405097","id":"PMC_9405097","title":"The POU gene ceh-18 promotes gonadal sheath cell differentiation and function required for meiotic maturation and ovulation in Caenorhabditis elegans.","date":"1997","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/9405097","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7958868","id":"PMC_7958868","title":"Targeted mutations in the Caenorhabditis elegans POU homeo box gene ceh-18 cause defects in oocyte cell cycle arrest, gonad migration, and epidermal differentiation.","date":"1994","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/7958868","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11060243","id":"PMC_11060243","title":"Overlapping roles of two Hox genes and the exd ortholog ceh-20 in diversification of the C. elegans postembryonic mesoderm.","date":"2000","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/11060243","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10774727","id":"PMC_10774727","title":"The LIM homeobox gene ceh-14 confers thermosensory function to the AFD neurons in Caenorhabditis elegans.","date":"2000","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/10774727","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16461282","id":"PMC_16461282","title":"Wnt signaling and CEH-22/tinman/Nkx2.5 specify a stem cell niche in C. elegans.","date":"2006","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/16461282","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18056428","id":"PMC_18056428","title":"The C. elegans protein CEH-30 protects male-specific neurons from apoptosis independently of the Bcl-2 homolog CED-9.","date":"2007","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/18056428","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21713031","id":"PMC_21713031","title":"The homeobox protein CEH-23 mediates prolonged longevity in response to impaired mitochondrial electron transport chain in C. elegans.","date":"2011","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/21713031","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12399316","id":"PMC_12399316","title":"Roles of the Homothorax/Meis/Prep homolog UNC-62 and the Exd/Pbx homologs CEH-20 and CEH-40 in C. elegans embryogenesis.","date":"2002","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12399316","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7789259","id":"PMC_7789259","title":"The C. elegans neuronally expressed homeobox gene ceh-10 is closely related to genes expressed in the vertebrate eye.","date":"1995","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/7789259","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18056429","id":"PMC_18056429","title":"Control of sex-specific apoptosis in C. elegans by the BarH homeodomain protein CEH-30 and the transcriptional repressor UNC-37/Groucho.","date":"2007","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/18056429","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10068646","id":"PMC_10068646","title":"Anterior organization of the Caenorhabditis elegans embryo by the labial-like Hox gene ceh-13.","date":"1999","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/10068646","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26817948","id":"PMC_26817948","title":"Sacubitril Is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation.","date":"2016","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/26817948","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10887091","id":"PMC_10887091","title":"The homeodomain protein CePHOX2/CEH-17 controls antero-posterior axonal growth in C. elegans.","date":"2000","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/10887091","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16160475","id":"PMC_16160475","title":"Distinct molecular alterations in complex endometrial hyperplasia (CEH) with and without immature squamous metaplasia (squamous morules).","date":"2005","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16160475","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19332024","id":"PMC_19332024","title":"Regulation of carboxylesterase 1 (CES1) in human adipose tissue.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19332024","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26076923","id":"PMC_26076923","title":"CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors.","date":"2015","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/26076923","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11820809","id":"PMC_11820809","title":"Conserved regulation of the Caenorhabditis elegans labial/Hox1 gene ceh-13.","date":"2002","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/11820809","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16421192","id":"PMC_16421192","title":"Direct regulation of egl-1 and of programmed cell death by the Hox protein MAB-5 and by CEH-20, a C. elegans homolog of Pbx1.","date":"2006","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16421192","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17289921","id":"PMC_17289921","title":"UNC-4 represses CEH-12/HB9 to specify synaptic inputs to VA motor neurons in C. elegans.","date":"2007","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/17289921","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26825642","id":"PMC_26825642","title":"Age-Dependent Human Hepatic Carboxylesterase 1 (CES1) and Carboxylesterase 2 (CES2) Postnatal Ontogeny.","date":"2016","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/26825642","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20975297","id":"PMC_20975297","title":"A dysregulation in CES1, APOE and other lipid metabolism-related genes is associated to cardiovascular risk factors linked to obesity.","date":"2010","source":"Obesity facts","url":"https://pubmed.ncbi.nlm.nih.gov/20975297","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31575861","id":"PMC_31575861","title":"Synthesis of clathrate cerium superhydride CeH9 at 80-100 GPa with atomic hydrogen sublattice.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31575861","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15659483","id":"PMC_15659483","title":"ceh-16/engrailed patterns the embryonic epidermis of Caenorhabditis elegans.","date":"2005","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15659483","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11171402","id":"PMC_11171402","title":"Regulation of ectodermal and excretory function by the C. elegans POU homeobox gene ceh-6.","date":"2001","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/11171402","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16033949","id":"PMC_16033949","title":"Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2).","date":"2005","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/16033949","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30956009","id":"PMC_30956009","title":"CEH-60/PBX and UNC-62/MEIS Coordinate a Metabolic Switch that Supports Reproduction in C. elegans.","date":"2019","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/30956009","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19605496","id":"PMC_19605496","title":"The NK-2 class homeodomain factor CEH-51 and the T-box factor TBX-35 have overlapping function in C. elegans mesoderm development.","date":"2009","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/19605496","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30100750","id":"PMC_30100750","title":"The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty.","date":"2018","source":"Pharmacogenomics and personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30100750","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34185414","id":"PMC_34185414","title":"Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1.","date":"2021","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34185414","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28087982","id":"PMC_28087982","title":"The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects.","date":"2017","source":"British journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28087982","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11476572","id":"PMC_11476572","title":"The Caenorhabditis elegans Six/sine oculis class homeobox gene ceh-32 is required for head morphogenesis.","date":"2001","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/11476572","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15095973","id":"PMC_15095973","title":"The C. elegans ceh-36 gene encodes a putative homemodomain transcription factor involved in chemosensory functions of ASE and AWC neurons.","date":"2004","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15095973","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9334268","id":"PMC_9334268","title":"The expression of the C. elegans labial-like Hox gene ceh-13 during early embryogenesis relies on cell fate and on anteroposterior cell polarity.","date":"1997","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/9334268","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20150279","id":"PMC_20150279","title":"The HMX/NKX homeodomain protein MLS-2 specifies the identity of the AWC sensory neuron type via regulation of the ceh-36 Otx gene in C. elegans.","date":"2010","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/20150279","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19651238","id":"PMC_19651238","title":"Es-x/Ces1 prevents triacylglycerol accumulation in McArdle-RH7777 hepatocytes.","date":"2009","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/19651238","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21081832","id":"PMC_21081832","title":"Depot-specific expression of lipolytic genes in human adipose tissues--association among CES1 expression, triglyceride lipase activity and adiposity.","date":"2010","source":"Journal of atherosclerosis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/21081832","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36472914","id":"PMC_36472914","title":"Interfering with lipid metabolism through targeting CES1 sensitizes hepatocellular carcinoma for chemotherapy.","date":"2023","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/36472914","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29407485","id":"PMC_29407485","title":"Presence and inter-individual variability of carboxylesterases (CES1 and CES2) in human lung.","date":"2018","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29407485","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31076985","id":"PMC_31076985","title":"Vitamin E Ameliorates Lipid Metabolism in Mice with Nonalcoholic Fatty Liver Disease via Nrf2/CES1 Signaling Pathway.","date":"2019","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31076985","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37042626","id":"PMC_37042626","title":"Loss of renal tubular G9a benefits acute kidney injury by lowering focal lipid accumulation via CES1.","date":"2023","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/37042626","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17640957","id":"PMC_17640957","title":"Haplotypes and a novel defective allele of CES2 found in a Japanese population.","date":"2007","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/17640957","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12810585","id":"PMC_12810585","title":"The Caenorhabditis elegans ems class homeobox gene ceh-2 is required for M3 pharynx motoneuron function.","date":"2003","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12810585","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24350812","id":"PMC_24350812","title":"Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene.","date":"2013","source":"Journal of child and adolescent psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24350812","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26587656","id":"PMC_26587656","title":"CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.","date":"2015","source":"Journal of neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/26587656","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29631096","id":"PMC_29631096","title":"Genetic variation in human carboxylesterase CES1 confers resistance to hepatic steatosis.","date":"2018","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/29631096","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25738873","id":"PMC_25738873","title":"The Bicoid class homeodomain factors ceh-36/OTX and unc-30/PITX cooperate in C. elegans embryonic progenitor cells to regulate robust development.","date":"2015","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25738873","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29263072","id":"PMC_29263072","title":"Effect of Genetic Variation of NAT2 on Isoniazid and SLCO1B1 and CES2 on Rifampin Pharmacokinetics in Ghanaian Children with Tuberculosis.","date":"2018","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/29263072","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35324425","id":"PMC_35324425","title":"The enteric nervous system of the C. elegans pharynx is specified by the Sine oculis-like homeobox gene ceh-34.","date":"2022","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/35324425","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19607822","id":"PMC_19607822","title":"The C. elegans engrailed homolog ceh-16 regulates the self-renewal expansion division of stem cell-like seam cells.","date":"2009","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/19607822","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32591414","id":"PMC_32591414","title":"Natural Products as Modulators of CES1 Activity.","date":"2020","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/32591414","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28560849","id":"PMC_28560849","title":"Transcription factors CEP-1/p53 and CEH-23 collaborate with AAK-2/AMPK to modulate longevity in Caenorhabditis elegans.","date":"2017","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/28560849","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15967118","id":"PMC_15967118","title":"Altered expression of TFF-1 and CES-2 in Barrett's Esophagus and associated adenocarcinomas.","date":"2005","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/15967118","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29259301","id":"PMC_29259301","title":"Global inactivation of carboxylesterase 1 (Ces1/Ces1g) protects against atherosclerosis in Ldlr -/- mice.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29259301","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31128980","id":"PMC_31128980","title":"Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention.","date":"2019","source":"Clinical therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/31128980","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25198900","id":"PMC_25198900","title":"CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.","date":"2014","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25198900","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17660295","id":"PMC_17660295","title":"Transcriptional regulation of AQP-8, a Caenorhabditis elegans aquaporin exclusively expressed in the excretory system, by the POU homeobox transcription factor CEH-6.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17660295","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29803178","id":"PMC_29803178","title":"MiR-155 inhibits transformation of macrophages into foam cells via regulating CEH expression.","date":"2018","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/29803178","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21177752","id":"PMC_21177752","title":"Carboxylesterase 1 (Ces1): from monocyte marker to major player.","date":"2010","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21177752","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25896426","id":"PMC_25896426","title":"Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics.","date":"2015","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/25896426","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35790245","id":"PMC_35790245","title":"The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro.","date":"2022","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/35790245","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23471941","id":"PMC_23471941","title":"Relationship between CES2 genetic variations and rifampicin metabolism.","date":"2013","source":"The Journal of antimicrobial chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/23471941","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39472448","id":"PMC_39472448","title":"Nicotine-induced CHRNA5 activation modulates CES1 expression, impacting head and neck squamous cell carcinoma recurrence and metastasis via MEK/ERK pathway.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/39472448","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26871237","id":"PMC_26871237","title":"Regulatory effects of genomic translocations at the human carboxylesterase-1 (CES1) gene locus.","date":"2016","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/26871237","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19643105","id":"PMC_19643105","title":"Two Hox cofactors, the Meis/Hth homolog UNC-62 and the Pbx/Exd homolog CEH-20, function together during C. elegans postembryonic mesodermal development.","date":"2009","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/19643105","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20667114","id":"PMC_20667114","title":"The C. elegans Hox gene ceh-13 regulates cell migration and fusion in a non-colinear way. Implications for the early evolution of Hox clusters.","date":"2010","source":"BMC developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/20667114","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32564268","id":"PMC_32564268","title":"Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran.","date":"2020","source":"Advances in therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32564268","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19931604","id":"PMC_19931604","title":"Relations between strain and gender dependencies of irinotecan toxicity and UGT1A1, CES2 and TOP1 expressions in mice.","date":"2009","source":"Toxicology letters","url":"https://pubmed.ncbi.nlm.nih.gov/19931604","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23608457","id":"PMC_23608457","title":"The LIM homeobox gene ceh-14 is required for phasmid function and neurite outgrowth.","date":"2013","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/23608457","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37796333","id":"PMC_37796333","title":"The homeodomain transcription factor CEH-37 regulates PMK-1/p38 MAPK pathway to protect against intestinal infection via the phosphatase VHP-1.","date":"2023","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/37796333","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15618752","id":"PMC_15618752","title":"Twelve novel single nucleotide polymorphisms in the CES2 gene encoding human carboxylesterase 2 (hCE-2).","date":"2003","source":"Drug metabolism and pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/15618752","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24204299","id":"PMC_24204299","title":"Coordination of cell proliferation and cell fate determination by CES-1 snail.","date":"2013","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24204299","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28639420","id":"PMC_28639420","title":"The Pharmacokinetics of Enalapril in Relation to CES1 Genotype in Healthy Danish Volunteers.","date":"2017","source":"Basic & clinical pharmacology & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/28639420","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33225149","id":"PMC_33225149","title":"Inactivation of CES1 Blocks Prostaglandin D2 Glyceryl Ester Catabolism in Monocytes/Macrophages and Enhances Its Anti-inflammatory Effects, Whereas the Pro-inflammatory Effects of Prostaglandin E2 Glyceryl Ester Are Attenuated.","date":"2020","source":"ACS omega","url":"https://pubmed.ncbi.nlm.nih.gov/33225149","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30801959","id":"PMC_30801959","title":"The impact of human CES1 genetic variation on enzyme activity assessed by ritalinic acid/methylphenidate ratios.","date":"2019","source":"Basic & clinical pharmacology & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/30801959","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11747075","id":"PMC_11747075","title":"The Caenorhabditis elegans distal-less ortholog ceh-43 is required for development of the anterior hypodermis.","date":"2001","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/11747075","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32134727","id":"PMC_32134727","title":"Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease.","date":"2020","source":"Drug metabolism and personalized therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32134727","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9443973","id":"PMC_9443973","title":"Effects of deletion mutations in the yeast Ces1 protein on cell growth and morphology and on high copy suppression of mutations in mRNA capping enzyme and translation initiation factor 4A.","date":"1998","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/9443973","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23480903","id":"PMC_23480903","title":"Clinical implications of CES2 RNA expression in neuroblastoma.","date":"2013","source":"Journal of pediatric surgery","url":"https://pubmed.ncbi.nlm.nih.gov/23480903","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12711598","id":"PMC_12711598","title":"Sequence-specific binding to telomeric DNA by CEH-37, a homeodomain protein in the nematode Caenorhabditis elegans.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12711598","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26340669","id":"PMC_26340669","title":"Fluoxetine reduces CES1, CES2, and CYP3A4 expression through decreasing PXR and increasing DEC1 in HepG2 cells.","date":"2015","source":"Xenobiotica; the fate of foreign compounds in biological systems","url":"https://pubmed.ncbi.nlm.nih.gov/26340669","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14738885","id":"PMC_14738885","title":"An early pharyngeal muscle enhancer from the Caenorhabditis elegans ceh-22 gene is targeted by the Forkhead factor PHA-4.","date":"2004","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/14738885","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36695375","id":"PMC_36695375","title":"Choline and trimethylamine N-oxide impair metabolic activation of and platelet response to clopidogrel through activation of the NOX/ROS/Nrf2/CES1 pathway.","date":"2022","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/36695375","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33738142","id":"PMC_33738142","title":"Enhancer RNA lnc-CES1-1 inhibits decidual cell migration by interacting with RNA-binding protein FUS and activating PPARγ in URPL.","date":"2021","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/33738142","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19458622","id":"PMC_19458622","title":"Exploring the diabetogenicity of the HLA-B18-DR3 CEH: independent association with T1D genetic risk close to HLA-DOA.","date":"2009","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/19458622","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34971802","id":"PMC_34971802","title":"CES2 sustains HNF4α expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop.","date":"2021","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34971802","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31675356","id":"PMC_31675356","title":"CEH-60/PBX regulates vitellogenesis and cuticle permeability through intestinal interaction with UNC-62/MEIS in Caenorhabditis elegans.","date":"2019","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/31675356","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28827188","id":"PMC_28827188","title":"Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer.","date":"2017","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/28827188","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32946434","id":"PMC_32946434","title":"PIG-1 MELK-dependent phosphorylation of nonmuscle myosin II promotes apoptosis through CES-1 Snail partitioning.","date":"2020","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32946434","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11783006","id":"PMC_11783006","title":"Multiple enhancers contribute to expression of the NK-2 homeobox gene ceh-22 in C. elegans pharyngeal muscle.","date":"2001","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/11783006","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32466188","id":"PMC_32466188","title":"Genetic Analysis Reveals a Significant Contribution of CES1 to Prostate Cancer Progression in Taiwanese Men.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32466188","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33963573","id":"PMC_33963573","title":"Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects.","date":"2021","source":"British journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33963573","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15931389","id":"PMC_15931389","title":"Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer.","date":"2005","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/15931389","citation_count":760,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11950776","id":"PMC_11950776","title":"Current progress on esterases: from molecular structure to function.","date":"2002","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/11950776","citation_count":241,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12960109","id":"PMC_12960109","title":"Irinotecan pathway genotype analysis to predict pharmacokinetics.","date":"2003","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/12960109","citation_count":209,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23467860","id":"PMC_23467860","title":"Genetic determinants of dabigatran plasma levels and their relation to bleeding.","date":"2013","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/23467860","citation_count":209,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21516116","id":"PMC_21516116","title":"Next-generation sequencing to generate interactome datasets.","date":"2011","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/21516116","citation_count":200,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17764701","id":"PMC_17764701","title":"Carboxylesterase in the liver and small intestine of experimental animals and human.","date":"2007","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17764701","citation_count":170,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12679808","id":"PMC_12679808","title":"Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme.","date":"2003","source":"Nature structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/12679808","citation_count":166,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23275066","id":"PMC_23275066","title":"Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation.","date":"2012","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/23275066","citation_count":166,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20931200","id":"PMC_20931200","title":"Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins.","date":"2010","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/20931200","citation_count":146,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12725862","id":"PMC_12725862","title":"Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition.","date":"2003","source":"Chemistry & biology","url":"https://pubmed.ncbi.nlm.nih.gov/12725862","citation_count":136,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23111421","id":"PMC_23111421","title":"The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response.","date":"2013","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/23111421","citation_count":135,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1918003","id":"PMC_1918003","title":"A serine esterase released by human alveolar macrophages is closely related to liver microsomal carboxylesterases.","date":"1991","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1918003","citation_count":128,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18983829","id":"PMC_18983829","title":"Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin.","date":"2008","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18983829","citation_count":126,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16962139","id":"PMC_16962139","title":"Multisite promiscuity in the processing of endogenous substrates by human carboxylesterase 1.","date":"2006","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16962139","citation_count":117,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34857952","id":"PMC_34857952","title":"Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers.","date":"2021","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34857952","citation_count":116,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11015575","id":"PMC_11015575","title":"Cholesteryl ester hydrolase in human monocyte/macrophage: cloning, sequencing, and expression of full-length cDNA.","date":"2000","source":"Physiological genomics","url":"https://pubmed.ncbi.nlm.nih.gov/11015575","citation_count":99,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15475243","id":"PMC_15475243","title":"Pharmacogenomic assessment of carboxylesterases 1 and 2.","date":"2004","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/15475243","citation_count":95,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8218228","id":"PMC_8218228","title":"Glycosylation-dependent activity of baculovirus-expressed human liver carboxylesterases: cDNA cloning and characterization of two highly similar enzyme forms.","date":"1993","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8218228","citation_count":95,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"31871135","id":"PMC_31871135","title":"Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators.","date":"2019","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/31871135","citation_count":92,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24141856","id":"PMC_24141856","title":"In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors.","date":"2013","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/24141856","citation_count":91,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19658107","id":"PMC_19658107","title":"Human plasma carboxylesterase 1, a novel serologic biomarker candidate for hepatocellular carcinoma.","date":"2009","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/19658107","citation_count":89,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9311626","id":"PMC_9311626","title":"Human liver carboxylesterase hCE-1: binding specificity for cocaine, heroin, and their metabolites and analogs.","date":"1997","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/9311626","citation_count":86,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12773168","id":"PMC_12773168","title":"Human carboxylesterase 1: from drug metabolism to drug discovery.","date":"2003","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/12773168","citation_count":82,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15188402","id":"PMC_15188402","title":"Proteins associated with type II bone morphogenetic protein receptor (BMPR-II) and identified by two-dimensional gel electrophoresis and mass spectrometry.","date":"2004","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/15188402","citation_count":77,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52201,"output_tokens":4056,"usd":0.108721},"stage2":{"model":"claude-opus-4-6","input_tokens":7524,"output_tokens":3607,"usd":0.191692},"total_usd":0.565307,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":66336,"output_tokens":9079,"usd":0.167597},"round2_rules_fired":"R2","round2_stage2":{"model":"claude-opus-4-6","input_tokens":12443,"output_tokens":106,"usd":0.097297}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"CES1 functions as a serine esterase that hydrolyzes methylphenidate; the missense variant p.Gly143Glu reduces catalytic efficiency to 21.4% of wild-type toward p-nitrophenyl acetate, and the frameshift variant p.Asp260fs reduces it to 0.6%, demonstrating that specific CES1 coding mutations cause loss of hydrolytic activity.\",\n      \"method\": \"In vitro functional assay (p-nitrophenyl acetate and methylphenidate hydrolysis) with recombinant wild-type and mutant CES1 proteins expressed in cell lines; Vmax/Km determination\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic assay with defined substrates and kinetic parameters for two distinct loss-of-function variants\",\n      \"pmids\": [\"18485328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Sacubitril (a prodrug for heart failure) is selectively activated by CES1 in the human liver; the CES1 variant G143E is a loss-of-function allele that significantly impairs sacubitril hydrolysis to its active metabolite sacubitrilat, as shown by selective inhibition in liver S9 fractions and recombinant enzyme assays.\",\n      \"method\": \"Incubation of sacubitril with human liver/intestine/kidney S9 fractions; specific CES1 inhibitor (bis-(p-nitrophenyl) phosphate); recombinant CES1 and CES2 assays; transfected cell lines expressing wild-type vs. G143E CES1\",\n      \"journal\": \"Drug metabolism and disposition: the biological fate of chemicals\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including selective inhibitor, recombinant enzyme, and human liver tissue with variant genotyping\",\n      \"pmids\": [\"26817948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CES1 selectively activates ACE inhibitor prodrugs (enalapril, ramipril, perindopril, moexipril, fosinopril) in the human liver; the G143E variant reduces enalapril activation activity to approximately one-third of wild-type in human liver samples.\",\n      \"method\": \"Incubation with human liver, intestine, and kidney S9 fractions; CES1 inhibitor experiments; transfected cell lines with wild-type and variant CES1; human liver sample genotyping with activity measurement\",\n      \"journal\": \"The pharmacogenomics journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro selectivity established with inhibitors and recombinant enzymes, validated in human tissue with genotype stratification\",\n      \"pmids\": [\"26076923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The CES1 G143E loss-of-function variant significantly impairs enalapril (prodrug) activation to enalaprilat in vivo, resulting in 27.5% lower enalaprilat AUC and 30.9% lower Cmax in G143E carriers, along with absence of the systolic blood pressure-lowering pharmacodynamic effect observed in non-carriers.\",\n      \"method\": \"Prospective multi-dose clinical PK/PD study; LC-MS/MS quantification of enalapril and enalaprilat plasma concentrations; genotype-stratified analysis\",\n      \"journal\": \"British journal of clinical pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean in vivo human PK/PD study with genotype stratification and direct pharmacodynamic endpoint measurement\",\n      \"pmids\": [\"33963573\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Mouse CES1 (Es-x/Ces1) prevents triacylglycerol accumulation in hepatocytes by promoting fatty acid beta-oxidation rather than by increasing TG hydrolysis; Es-x expression reduced cellular TG accumulation in the presence of esterase inhibitor E600, indicating a mechanism of redirecting fatty acids away from TG synthesis toward beta-oxidation.\",\n      \"method\": \"Stable transfection of McArdle-RH7777 hepatocytes with Es-x cDNA; measurement of acid-soluble metabolites (beta-oxidation indicator); incubation with oleic acid; esterase inhibitor E600 experiments\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — cell-based functional assay with multiple conditions but single lab and single cell model\",\n      \"pmids\": [\"19651238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Human CES1 with the G143E variant (only 20% of wild-type lipolytic activity) expressed in a humanized mouse model (lacking endogenous mouse ortholog) reduces liver and plasma triacylglycerol levels through decreased VLDL secretion, reduced hepatic lipogenic gene expression, and increased fatty acid oxidation (increased ketone bodies and mitochondrial electron transport chain protein).\",\n      \"method\": \"Humanized mouse model expressing CES1WT, CES1G143E, or catalytically dead CES1S221A in liver; high-fat diet; measurement of TG levels, VLDL secretion, plasma ketone bodies, mitochondrial ETC proteins\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular and cell biology of lipids\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vivo reconstitution in humanized mouse with catalytic dead control, multiple orthogonal metabolic readouts\",\n      \"pmids\": [\"29631096\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Global knockout of mouse Ces1/Ces1g protects against atherosclerosis by inhibiting intestinal cholesterol and fat absorption (reducing NPC1L1 expression) and promoting macrophage cholesterol efflux (inducing ABCA1 and ABCG1), and promotes M2 macrophage polarization and hepatic bile acid synthesis enzymes.\",\n      \"method\": \"Ces1g-/- and Ces1g-/- Ldlr-/- double knockout mice on Western diet; measurement of atherosclerotic lesions, plasma lipids, intestinal absorption, macrophage cholesterol efflux, gene expression\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo knockout with multiple mechanistic readouts, but some mechanistic steps are correlative\",\n      \"pmids\": [\"29259301\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CES1 in human monocytes/macrophages (THP-1 cells) catabolizes prostaglandin D2-glyceryl ester (PGD2-G), accounting for ~50% of its hydrolytic metabolism; pharmacological or genetic knockdown of CES1 stabilizes PGD2-G and augments its anti-inflammatory effects (reduced IL-6 and TNFα), while PGE2-G pro-inflammatory effects are also modulated through CES1 hydrolysis.\",\n      \"method\": \"CES1 inhibitors (CPO, WWL229, WWL113) in THP-1 cells; CES1 knockdown (CES1KD) cells; LC-MS/MS quantification of PGD2-G and PGD2; cytokine measurements; PPARγ activation assay\",\n      \"journal\": \"ACS omega\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple inhibitors and genetic knockdown with defined substrate and functional inflammatory readouts in one lab\",\n      \"pmids\": [\"33225149\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CES1 inhibition in hepatocellular carcinoma cells reduces polyunsaturated fatty acids (PUFAs) that activate PPARα/γ, leading to decreased SCD expression (a PPARα/γ target involved in tumor progression), thereby sensitizing HCC cells to cisplatin; this CES1-PPARα/γ-SCD axis was validated in xenograft mouse models.\",\n      \"method\": \"Pharmacological and genetic CES1 inhibition in HCC cell lines; lipidomic analysis; PPARα/γ activation assays; SCD expression measurement; xenograft mouse model with cisplatin co-administration\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway (CES1→PUFA→PPARα/γ→SCD) established with multiple orthogonal methods in one study\",\n      \"pmids\": [\"36472914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"G9a histone methyltransferase suppresses Ces1 transcription in renal tubular cells by competing with FXR at Ces1 promoter regions; loss of G9a elevates Ces1 expression, reducing lipid accumulation and protecting against acute kidney injury.\",\n      \"method\": \"Renal tubular-specific G9a knockout mice; pharmacological G9a inhibition; Ces1 pharmacological inhibition; promoter binding studies showing G9a and FXR competition; AKI models (ischemia-reperfusion, cisplatin)\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic and pharmacological evidence with defined promoter binding competition mechanism\",\n      \"pmids\": [\"37042626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TMAO increases CES1 protein expression and activity in the liver through activation of the NOX-dependent ROS/Nrf2/CES1 pathway, leading to increased clopidogrel hydrolysis and impaired formation of the active clopidogrel metabolite, thereby reducing antiplatelet response.\",\n      \"method\": \"TMAO- or choline-fed mice with clopidogrel treatment; measurement of clopidogrel and metabolite plasma concentrations; platelet aggregation assays; HepG2 cells treated with TMAO ± N-acetyl-L-cysteine, ML385 (Nrf2 inhibitor), or apocynin; CES1, ROS, and Nrf2 measurements\",\n      \"journal\": \"Journal of thrombosis and haemostasis: JTH\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo and in vitro orthogonal experiments with pathway inhibitors defining NOX/ROS/Nrf2/CES1 axis\",\n      \"pmids\": [\"36695375\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Fluoxetine decreases CES1 expression and hydrolytic activity in HepG2 cells through a mechanism involving decreased PXR (pregnane X receptor) expression and increased DEC1; overexpression of PXR attenuates the FLX-induced CES1 decrease, while PXR knockdown abolishes it, establishing PXR as a transcriptional regulator of CES1.\",\n      \"method\": \"HepG2 cell transfections with PXR overexpression and siRNA knockdown; DEC1 siRNA knockdown; CES1 expression and enzymatic activity measurements; fluoxetine treatment\",\n      \"journal\": \"Xenobiotica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — reciprocal gain/loss-of-function experiments in cell lines establishing PXR as CES1 transcriptional regulator\",\n      \"pmids\": [\"26340669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Melatonin regulates CES1 expression through epigenetic modification in prostate cancer cells; restoration of CES1 expression by melatonin reduces lipid droplet accumulation, induces apoptosis via increased endoplasmic reticulum stress, reduces de novo intratumoral androgen synthesis, and reverses enzalutamide resistance.\",\n      \"method\": \"Animal CRPC models with circadian rhythm disorder; PCa cell lines; Ces1 knockout (Ces1-/-) mice; CES1 expression restoration experiments; lipid droplet quantification; ER stress markers; androgen synthesis measurement\",\n      \"journal\": \"Clinical and translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — in vivo Ces1-KO mouse validation and multiple cellular mechanistic readouts, but epigenetic mechanism not fully resolved\",\n      \"pmids\": [\"34185414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Hepatic CES1 protein abundance shows age-dependent maturation in humans, increasing approximately 5-fold from neonates to adults in liver microsomes, and CES1 protein abundance correlates with oseltamivir carboxylase activity in pediatric and adult liver microsomes.\",\n      \"method\": \"LC-MS/MS targeted proteomics with purified CES1 calibrators in 136 pediatric and 35 adult donor liver microsomes and cytosol; correlation with enzymatic activity measurement\",\n      \"journal\": \"Drug metabolism and disposition: the biological fate of chemicals\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — quantitative proteomics correlated directly with enzymatic activity across a large human tissue cohort\",\n      \"pmids\": [\"27895113\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CHRNA5 activation by nicotine regulates CES1 expression in head and neck squamous cell carcinoma cells via the MEK/ERK signaling pathway; CHRNA5 and CES1 physically interact (co-immunoprecipitation), and CES1 levels decrease upon CHRNA5 knockdown and increase upon nicotine-mediated CHRNA5 activation, with corresponding changes in p-MEK and p-ERK.\",\n      \"method\": \"CHRNA5 knockdown and overexpression; co-immunoprecipitation; immunofluorescence; western blot for p-MEK/MEK and p-ERK/ERK and CES1; nude mouse tumor formation assays; immunohistochemistry of clinical tissue\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, Co-IP shows interaction but mechanistic details of CES1 regulation by CHRNA5-MEK/ERK require further validation\",\n      \"pmids\": [\"39472448\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CES1 is a serine esterase expressed predominantly in human liver that catalyzes the hydrolysis of ester and amide bonds in numerous therapeutic prodrugs (including methylphenidate, sacubitril, ACE inhibitor prodrugs, and clopidogrel), endogenous lipid mediators (prostaglandin glyceryl esters), and triacylglycerols; its catalytic activity is abolished by the G143E (Gly143Glu) variant, and its expression is transcriptionally regulated by PXR and epigenetically by G9a methyltransferase and Nrf2 signaling, while its lipid-metabolizing function links it to hepatic VLDL secretion, fatty acid oxidation, macrophage cholesterol efflux, and tumor lipid metabolism via PPARα/γ-SCD axis.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll systematically classify each paper, then extract discoveries only from KEEP papers.\n\n**Classification summary:**\n- Papers about C. elegans CEH-genes (ceh-10, ceh-13, ceh-16, ceh-17, ceh-18, ceh-20, ceh-22, ceh-23, ceh-30, ceh-32, ceh-34, ceh-36, ceh-37, ceh-43, ceh-51, ceh-60, ces-1/ces-2 in C. elegans) → EXCLUDE (symbol collision/alias collision with nematode homeobox genes)\n- Papers about CES2, CES3 only (not CES1) → EXCLUDE\n- Paper about yeast Ces1p (Saccharomyces cerevisiae) → EXCLUDE (symbol collision, entirely different protein)\n- Paper about lnc-CES1-1 (enhancer RNA) → EXCLUDE (alt-locus product)\n- Paper about CeH9 (cerium superhydride) → EXCLUDE (symbol collision)\n- Papers about CEH in context of \"complex endometrial hyperplasia\" → EXCLUDE (acronym collision)\n- Papers about HLA CEH haplotype → EXCLUDE (acronym collision)\n- Papers clearly about human CES1 (carboxylesterase 1) protein → KEEP\n\n**KEEP papers:** 2, 4 (partial CES1A1), 6, 8, 9, 13 (curated list), 14 (curated), 16 (curated), 17 (curated), 18 (curated), 19 (curated), 20 (curated), 21, 22 (curated), 23 (curated), 24, 25, 26 (curated), 27 (curated), 28 (curated), 29 (curated), 30 (curated from gene2pubmed), 38, 44, 45, 46, 47, 48, 49, 52, 54, 59, 62, 66, 71, 72, 82, 83, 89, 91, 99, 100\n\nFrom retrieved papers: [2], [4], [6], [8], [21], [24], [25], [38], [44], [45], [46], [47], [48], [49], [52], [54], [59], [62], [66], [71], [72], [82], [83], [89], [91], [99], [100]\nFrom gene2pubmed papers: [8], [13], [14], [15], [16], [17], [18], [19], [20], [22], [23], [24], [25], [26], [27], [28], [29]\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1991,\n      \"finding\": \"CES1 (carboxylesterase 1) is expressed as a serine esterase in human alveolar macrophages and monocytes, where it is released into bronchoalveolar lavage fluid associated with surfactant; it is virtually identical to liver microsomal carboxylesterase, establishing CES1 as both a hepatic and macrophage enzyme with detoxification function.\",\n      \"method\": \"Protein purification, [3H]DFP labeling, NH2-terminal sequencing, PCR cloning from macrophage cDNA library, Northern blot\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods: purification, active-site labeling, sequencing, cloning, expression confirmation\",\n      \"pmids\": [\"1918003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"CES1 (hCE) encodes a 568-amino-acid serine hydrolase with an 18-aa signal peptide; baculovirus-expressed hCE hydrolyzes aromatic and aliphatic esters but not amides or fatty acyl-CoA esters; N-glycosylation is essential for maximal catalytic activity, as tunicamycin inhibition substantially reduces activity; two highly similar variants (hCE and hCEv) were identified as distinct gene family members.\",\n      \"method\": \"cDNA cloning, baculovirus expression in Sf9 cells, enzymatic assays, tunicamycin inhibition, somatic cell hybrid chromosome mapping\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted enzyme activity with mutagenesis-equivalent variant comparison and glycosylation inhibition\",\n      \"pmids\": [\"8218228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Purified human liver CES1 (hCE-1) catalyzes hydrolysis of cocaine to benzoylecgonine, deacetylation of heroin to 6-acetylmorphine, and ethanol-dependent transesterification of cocaine to cocaethylene; binding is stereoselective for (R)-(-)-cocaine, and the methyl ester, benzoyl, and N-methyl groups of cocaine are critical for binding affinity.\",\n      \"method\": \"Purified enzyme kinetic assays, competitive inhibition with 4-methylumbelliferyl acetate, stereoisomer comparison\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with purified enzyme, multiple substrates and stereoisomers\",\n      \"pmids\": [\"9311626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CES1 expressed in human macrophages functions as a cholesteryl ester hydrolase (CEH); overexpression in COS cells yielded >20-fold increased CEH activity; overexpression in CHO-K1 cells impaired LDL receptor mRNA upregulation under cholesterol-deficient conditions, placing CES1 in the intracellular cholesteryl ester metabolism pathway.\",\n      \"method\": \"RT-PCR, cDNA cloning, transient transfection in COS-1/COS-7/CHO-K1 cells, enzymatic activity assay, Northern blot\",\n      \"journal\": \"Physiological genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstituted activity in transfected cells with defined functional (LDL receptor) phenotypic readout\",\n      \"pmids\": [\"11015575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Crystal structures of human CES1 (hCE1) in complex with the cocaine analog homatropine and heroin analog naloxone reveal that the active site contains both a specific and a promiscuous compartment enabling metabolism of structurally distinct chemicals; a separate surface ligand-binding site regulates the trimer-hexamer equilibrium and allows each monomer to bind two narcotic molecules simultaneously.\",\n      \"method\": \"X-ray crystallography of hCE1 glycoprotein complexes\",\n      \"journal\": \"Nature structural biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures with functional interpretation, multiple complexes\",\n      \"pmids\": [\"12679808\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Crystal structure of hCE1 with tacrine (2.4 Å) shows tacrine binds in multiple orientations within the catalytic gorge, in contrast to acetylcholinesterase; this promiscuity is structurally explained by the larger, flexible active-site architecture of hCE1; tacrine derivatives were identified as low-micromolar CES1 inhibitors.\",\n      \"method\": \"X-ray crystallography, inhibitor screening assays\",\n      \"journal\": \"Chemistry & biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure with functional inhibitor validation\",\n      \"pmids\": [\"12725862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CES1A1 (along with CES2 and CES3) hydrolyzes irinotecan and its oxidative metabolites NPC and APC to the active metabolite SN-38; the relative catalytic efficiency for CPT-11 hydrolysis is CES2 > CES1A1 >> CES3.\",\n      \"method\": \"Purified recombinant enzyme kinetic assays\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — purified recombinant enzymes with full kinetic characterization\",\n      \"pmids\": [\"15100172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Crystal structures of hCE1 with CoA, palmitate, cholate, and taurocholate reveal three ligand-binding sites (active site plus two additional sites), all exhibiting non-specific binding; this multisite promiscuity structurally explains CES1's ability to perform cholesterol ester hydrolysis, fatty acyl-CoA hydrolysis, acyl-CoA:cholesterol acyltransfer, and fatty acyl ethyl ester synthesis depending on cellular context.\",\n      \"method\": \"X-ray crystallography of four hCE1 complexes with endogenous substrates/analogs\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — four crystal structures establishing structural basis of multisite catalytic promiscuity\",\n      \"pmids\": [\"16962139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Two CES1 coding mutations, p.Gly143Glu (exon 4) and p.Asp260fs (exon 6 frameshift/premature stop), cause complete loss of hydrolytic activity toward methylphenidate; p.Gly143Glu retains only 21.4% catalytic efficiency (Vmax/Km) and p.Asp260fs retains 0.6% relative to wild-type using p-nitrophenyl acetate; minor allele frequency of p.Gly143Glu is 3.7%/4.3%/2.0%/0% in white/black/Hispanic/Asian populations.\",\n      \"method\": \"DNA sequencing, in vitro functional expression, kinetic assays with methylphenidate and p-nitrophenyl acetate\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzyme activity assays with two distinct substrates, population frequency determination\",\n      \"pmids\": [\"18485328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Human CES1 (HCE1) is expressed predominantly in liver and shows age-dependent ontogeny: fetal liver has lowest expression (~10-fold lower than adult), child liver is intermediate; CES1 selectively hydrolyzes oseltamivir over CES2, and adult microsomes are ~4× more active than child and ~10× more active than fetal microsomes; large inter-individual variability (up to 100-fold in protein) exists within the same age group.\",\n      \"method\": \"RT-qPCR, Western immunoblotting across 104 liver samples (fetal, child, adult), hydrolytic activity assays\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — large sample proteomics with correlated functional activity, multiple substrates\",\n      \"pmids\": [\"18983829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Mouse esterase-x/Ces1 (Es-x/Ces1), stably expressed in McArdle-RH7777 hepatocytes, reduces triacylglycerol (TG) accumulation by redirecting exogenous fatty acids toward beta-oxidation rather than TG synthesis, as evidenced by increased acid-soluble metabolites; this TG-lowering effect persisted with esterase inhibitor E600, indicating the mechanism is primarily reduction of fatty acid partitioning into TG rather than increased TG turnover; Es-x expression did not alter VLDL-TG or apolipoprotein B secretion.\",\n      \"method\": \"Stable transfection of McArdle-RH7777 cells, TG quantification, acid-soluble metabolite measurement, E600 inhibitor experiment, glycerol supplementation\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function in defined cell line with pharmacological inhibitor dissection and multiple metabolic readouts\",\n      \"pmids\": [\"19651238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CES1 is the primary enzyme responsible for hydrolytic inactivation of clopidogrel and its intermediate 2-oxo-clopidogrel in human liver S9 fractions; inhibition of CES1 by bis(4-nitrophenyl) phosphate significantly increased concentrations of clopidogrel active metabolite; CES1 variants G143E and D260fs have completely impaired catalytic activity toward clopidogrel and 2-oxo-clopidogrel, whereas variants G18V, S82L, and A269S show no significant effect.\",\n      \"method\": \"Human liver S9 fraction incubations, CES1 inhibitor experiments, transfected cell line S9 fractions, LC-MS/MS metabolite quantification\",\n      \"journal\": \"The Journal of pharmacology and experimental therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — inhibitor dissection plus variant functional characterization with defined substrate metabolite profiles\",\n      \"pmids\": [\"23275066\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The CES1 G143E variant carriers show significantly increased clopidogrel active metabolite levels and better clopidogrel response (reduced ADP-stimulated platelet aggregation) compared with non-carriers, confirming that CES1-mediated hydrolysis constitutes the primary inactivation route of clopidogrel in vivo.\",\n      \"method\": \"Clinical pharmacogenomics study (PAPI study, n=566 + 350 CHD patients), active metabolite measurement, platelet aggregation assay\",\n      \"journal\": \"Pharmacogenetics and genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clinical validation of in vitro mechanistic finding, two independent cohorts\",\n      \"pmids\": [\"23111421\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Recombinant human CES1 efficiently hydrolyzes enalapril, ramipril, and trandolapril (but not CES2), establishing CES1 as the primary activating enzyme for these ACE inhibitor prodrugs; enalapril shows substrate inhibition kinetics while ramipril and trandolapril follow Michaelis-Menten kinetics; isradipine and tacrolimus are identified as novel CES1 inhibitors.\",\n      \"method\": \"Recombinant enzyme assays, Michaelis-Menten/substrate inhibition kinetic modeling, inhibitor screening with human liver microsomes\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — purified recombinant enzyme kinetics with multiple substrates and inhibitor identification\",\n      \"pmids\": [\"24141856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CES1 selectively activates ACE inhibitor prodrugs enalapril, ramipril, perindopril, moexipril, and fosinopril in human liver (not intestine or kidney); the G143E variant is a loss-of-function variant reducing enalapril activation to ~one-third of wild-type in human liver samples carrying the 143G/E genotype; neither CES1/CES1VAR nor CES1P1/CES1P1VAR genotypes/diplotypes affected hepatic CES1 expression or activity in normal liver samples.\",\n      \"method\": \"Human liver/intestine/kidney S9 fraction incubations, CES1 inhibitor (BNPP), recombinant transfected cell lines, 102 normal human liver samples\",\n      \"journal\": \"The pharmacogenomics journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — organ selectivity established with inhibitor, genetic variant functional characterization in human liver samples\",\n      \"pmids\": [\"26076923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Fluoxetine decreases CES1 expression and hydrolytic activity in HepG2 cells by decreasing pregnane X receptor (PXR) expression and increasing DEC1; PXR overexpression attenuated and PXR knockdown abolished CES1 decreases; DEC1 knockdown increased PXR and restored CES1, establishing a FLX→DEC1↑/PXR↓→CES1↓ transcriptional regulatory axis.\",\n      \"method\": \"HepG2 cell transfection (overexpression and siRNA knockdown), RT-PCR, Western blot, enzymatic activity assay\",\n      \"journal\": \"Xenobiotica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional genetic manipulation (OE + KD) establishing epistatic transcriptional pathway\",\n      \"pmids\": [\"26340669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Sacubitril is selectively activated (hydrolyzed) by CES1 in human liver S9 fractions but not by CES2 or in intestine/kidney/plasma; the G143E variant is a loss-of-function variant for sacubitril activation; human livers with G143E genotype show significantly impaired sacubitril activation.\",\n      \"method\": \"Incubation with human tissue S9 fractions, CES1-selective inhibitor BNPP, recombinant CES1 and CES2, transfected cell lines, human liver samples with G143E genotyping\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple complementary approaches establishing organ/enzyme selectivity and loss-of-function variant\",\n      \"pmids\": [\"26817948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The CES1VAR genomic translocation (replacing 5'UTR, exon 1, and part of intron 1 with CES1P1 pseudogene sequence, minor allele frequency 17%) reduces CES1 mRNA by ~2.6-fold and allelic mRNA by ~1.35-fold; however, CES1VAR did not detectably alter CES1 protein expression or metabolizing activity toward enalapril, clopidogrel, or methylphenidate in liver.\",\n      \"method\": \"Sanger and Ion Torrent sequencing, allelic mRNA analysis (SNaPshot), quantitative targeted proteomics, luciferase reporter assays in HepG2\",\n      \"journal\": \"Pharmacogenetics and genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including proteomics and reporter assays in liver tissue\",\n      \"pmids\": [\"26871237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CES1 and CES2 protein abundance in human liver microsomes increases approximately 5-fold and 3-fold from neonates to adults, respectively; oseltamivir carboxylase activity correlates with CES1 protein abundance across pediatric and adult liver microsomes, validating the ontogeny function for PBPK modeling.\",\n      \"method\": \"LC-MS/MS proteomics with purified protein standards as calibrators and heavy-labeled peptide internal standards in 171 liver samples\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — quantitative proteomics with functional correlation across large sample set\",\n      \"pmids\": [\"27895113\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The CES1 G143E variant (p.Gly143Glu) reduces lipolytic activity to ~20% of wild-type; humanized mice expressing CES1G143E on a Ces1-null background fed a high-fat diet show reduced liver and plasma triacylglycerol levels; the hypolipidemic mechanism involves decreased VLDL secretion, decreased hepatic lipogenic gene expression, and increased fatty acid oxidation (elevated plasma ketone bodies and hepatic mitochondrial electron transport chain protein abundance).\",\n      \"method\": \"Humanized mouse model (liver-specific CES1WT, CES1G143E, CES1S221A expression on Ces1-/- background), high-fat diet feeding, TG/cholesterol measurements, lipogenic gene expression, ketone body assay, mitochondrial protein quantification\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular and cell biology of lipids\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — humanized mouse model with catalytic-dead control, multiple mechanistic readouts\",\n      \"pmids\": [\"29631096\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Global inactivation of Ces1/Ces1g in Ldlr-/- mice protects against atherosclerosis by inhibiting intestinal cholesterol and fat absorption (including reduced Niemann-Pick C1-like 1 expression), increasing macrophage cholesterol efflux (via ABCA1 and ABCG1 induction), promoting M2 macrophage polarization, and inducing hepatic cholesterol 7α-hydroxylase and sterol 12α-hydroxylase; paradoxically, hepatic-specific Ces1/Ces1g knockdown in Apoe-/- mice exacerbated atherogenesis.\",\n      \"method\": \"Ces1g-/- Ldlr-/- double knockout mice, Western diet feeding, atherosclerotic lesion quantification, intestinal cholesterol absorption assay, macrophage cholesterol efflux assay, gene expression analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with multiple mechanistic readouts and organ-specific knockdown comparison\",\n      \"pmids\": [\"29259301\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Vitamin E reverses NAFLD-associated lipid accumulation in fructose-treated mice via upregulation of Nrf2 and CES1; the Nrf2 inhibitor ML385 abolished the protective effects of vitamin E on lipid metabolism, establishing a Nrf2→CES1 signaling axis in hepatic lipid homeostasis.\",\n      \"method\": \"NAFLD mouse model (fructose feeding), vitamin E treatment, Nrf2 inhibitor (ML385), histopathology, lipid assays, in vitro L02 cell experiments\",\n      \"journal\": \"Digestive diseases and sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — pharmacological inhibitor establishes pathway but mechanistic link between Nrf2 and CES1 relies on inhibitor alone\",\n      \"pmids\": [\"31076985\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CES1 is the most abundant drug-metabolizing enzyme in human liver (~1% of entire liver proteome), responsible for 80-95% of total hepatic hydrolytic activity; alcohol is identified as a potent CES1 inhibitor that can alter therapeutic outcomes of CES1 substrate medications.\",\n      \"method\": \"Proteomic quantification studies (reviewed), inhibitor characterization studies (reviewed)\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — review synthesizing proteomic abundance data and inhibition studies, single review paper\",\n      \"pmids\": [\"31871135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CES1 in human monocytic THP-1 cells hydrolyzes prostaglandin D2-glyceryl ester (PGD2-G), accounting for ~50% of its hydrolytic metabolism; CES1 knockdown or pharmacological inhibition (CPO, WWL113, WWL229) stabilizes PGD2-G, augmenting its anti-inflammatory effects (reduced IL-6, TNFα) upon LPS stimulation; PGD2-G (and/or downstream metabolites) activates PPARγ, altering alternative macrophage activation; inhibitor potency rank order: CPO > WWL113 > WWL229.\",\n      \"method\": \"THP-1 cell CES1 knockdown (siRNA), CES1 inhibitor dose-response, LC-MS/MS metabolite quantification, cytokine ELISA, PPARγ activation assay\",\n      \"journal\": \"ACS omega\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KD plus pharmacological inhibition with orthogonal readouts establishing CES1 as PGD2-G hydrolase in macrophages\",\n      \"pmids\": [\"33225149\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Melatonin treatment restores CES1 expression in prostate cancer cells via epigenetic modification; restored CES1 expression reduces lipid droplet accumulation, induces ER stress-mediated apoptosis, and reduces intratumoral androgen synthesis; Ces1-knockout mice show increased PCa tumor growth, confirming CES1's tumor-suppressive role via lipid metabolism regulation.\",\n      \"method\": \"Animal CRPC models, PCa cell lines, Ces1-/- mouse model, lipid droplet quantification, apoptosis assays, androgen synthesis measurement, epigenetic assays\",\n      \"journal\": \"Clinical and translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — knockout mouse and cell line experiments with multiple readouts; epigenetic mechanism not fully defined\",\n      \"pmids\": [\"34185414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CES1 G143E heterozygous carriers show 30.9% lower enalaprilat Cmax and 27.5% lower enalaprilat AUC0-∞ at steady state compared to non-carriers; carriers also showed no statistically significant blood pressure reduction vs ~12.4% reduction in non-carriers, directly linking CES1 loss-of-function to impaired prodrug activation and pharmacodynamic effect in vivo.\",\n      \"method\": \"Prospective multi-dose PK/PD clinical study, LC-MS/MS quantification, blood pressure monitoring\",\n      \"journal\": \"British journal of clinical pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — prospective clinical trial with PK and PD endpoints linking genetic variant to functional consequence\",\n      \"pmids\": [\"33963573\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TMAO (trimethylamine N-oxide) increases Ces1 protein expression and activity in mouse liver and HepG2 cells via a NOX-dependent ROS/Nrf2/CES1 pathway, leading to increased clopidogrel hydrolysis (inactivation) and impaired platelet response; co-administration of TMAO-synthesis inhibitor (3,3-dimethyl-1-butanol), antioxidant (N-acetyl-L-cysteine), or Nrf2 inhibitor (ML385) reversed these effects.\",\n      \"method\": \"Mouse dietary TMAO/choline feeding, pharmacological pathway dissection (FMO inhibitor, antioxidant, Nrf2 inhibitor), HepG2 cell treatment, Ces1 protein/activity measurement, clopidogrel metabolite LC-MS/MS, platelet aggregation assay\",\n      \"journal\": \"Journal of thrombosis and haemostasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological inhibitors at different pathway nodes in both in vivo and in vitro models\",\n      \"pmids\": [\"36695375\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CES1 inhibition (pharmacological or siRNA) in hepatocellular carcinoma cells alters lipid profiles by reducing polyunsaturated fatty acids (PUFAs), which activates PPARα/γ; loss of PPARα/γ activation downregulates the target gene SCD (involved in chemoresistance); the CES1-PPARα/γ-SCD axis sensitizes HCC cells to cisplatin, and co-administration of cisplatin with CES1 inhibition slows xenograft tumor growth.\",\n      \"method\": \"Pharmacological CES1 inhibition, siRNA knockdown, lipidomic analysis, PPARα/γ pathway analysis, SCD expression measurement, cisplatin sensitivity assays, xenograft mouse model\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — lipidomics plus genetic and pharmacological inhibition establishing mechanistic pathway with in vivo validation\",\n      \"pmids\": [\"36472914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"G9a (Ehmt2-encoded histone methyltransferase) suppresses transcription of Ces1 in renal tubules; G9a and farnesoid X receptor (FXR) competitively bind to the same promoter regions of Ces1; tubular-specific G9a knockout (Ehmt2Ksp) or G9a inhibition derepresses Ces1, reducing lipid accumulation and alleviating AKI; pharmacological Ces1 inhibition reverses the AKI-protective effect of Ehmt2Ksp mice, establishing a G9a/FXR-Ces1 axis controlling renal lipid homeostasis.\",\n      \"method\": \"Renal tubular-specific G9a knockout mice, pharmacological G9a inhibition, Ces1 pharmacological inhibition, chromatin binding assays (G9a vs FXR competition at Ces1 promoter), lipid staining, AKI model (I/R and cisplatin), atorvastatin and FXR agonist treatment\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — conditional knockout with promoter competition mechanism, multiple genetic and pharmacological epistasis experiments\",\n      \"pmids\": [\"37042626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Nicotine activates CHRNA5 in head and neck squamous cell carcinoma cells, which physically interacts with CES1 (confirmed by co-immunoprecipitation and molecular docking); CHRNA5 activation via the MEK/ERK pathway upregulates CES1 expression; CHRNA5 knockdown reduces CES1 mRNA and protein levels, an effect reversed by nicotine exposure.\",\n      \"method\": \"Co-immunoprecipitation, molecular docking, immunofluorescence, CHRNA5 knockdown/overexpression, Western blot for p-MEK/MEK, p-ERK/ERK and CES1, nude mouse tumor formation assay\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP establishes CHRNA5-CES1 interaction; MEK/ERK regulation supported by knockdown but single lab\",\n      \"pmids\": [\"39472448\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CES1 in human lungs is present predominantly in the microsomal fraction with 30-50-fold higher Vmax for pNPA (CES1 marker substrate) compared to FD (CES2 marker); CES1 and CES2 show 2.5-5-fold and 8-15-fold inter-individual variation in lung hydrolytic activity, respectively, demonstrating CES1 as the dominant esterase in human lung tissue.\",\n      \"method\": \"Cytosol and microsomal fractionation of 20 human lung samples, kinetic assays (Vmax, Km), selective inhibitor studies (loperamide for CES2, BNPP, PMSF)\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — kinetic characterization with selective inhibitors across multiple tissue samples establishing CES1 as dominant lung esterase\",\n      \"pmids\": [\"29407485\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"MiR-155 overexpression in THP-1 macrophages upregulates CES1 (CEH) mRNA and protein in a dose- and time-dependent manner; miR-155-mediated CEH induction reduces intracellular cholesteryl ester accumulation and foam cell formation; siRNA knockdown of CEH reverses miR-155's anti-foam cell effect; Tim-3 overexpression attenuates miR-155-mediated CEH induction, placing Tim-3 upstream of the miR-155/CES1 axis.\",\n      \"method\": \"miR-155 mimic transfection, siCEH knockdown, Tim-3 overexpression in THP-1 macrophages, cholesterol efflux assay, lipid accumulation quantification, RT-PCR and Western blot\",\n      \"journal\": \"Biomedicine & pharmacotherapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — gain and loss of function with functional readout; regulatory mechanism partially defined\",\n      \"pmids\": [\"29803178\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Human CES1 is a serine hydrolase primarily localized in hepatic microsomes and macrophages where it catalyzes the hydrolysis, transesterification, and activation of diverse substrates including drugs (clopidogrel, methylphenidate, ACE inhibitor prodrugs, sacubitril), narcotics (cocaine, heroin), and endogenous lipids (cholesteryl esters, prostaglandin glyceryl esters, triacylglycerols); its crystal structures reveal a promiscuous active site with multiple ligand-binding sites; N-glycosylation is required for maximal activity; the loss-of-function variant G143E abolishes or severely impairs activity toward all tested substrates; CES1 expression is transcriptionally regulated by PXR/DEC1, Nrf2, G9a/FXR, and miR-155/Tim-3 axes; and through lipid substrate metabolism, CES1 controls hepatic VLDL secretion, macrophage cholesterol efflux, renal lipid homeostasis, and tumor lipid signaling via PPARα/γ-SCD.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CES1 is a hepatic serine esterase that hydrolyzes ester and amide bonds in a broad range of therapeutic prodrugs and endogenous lipid substrates, thereby governing both drug activation and intracellular lipid homeostasis. CES1 catalyzes the bioactivation of methylphenidate, ACE inhibitor prodrugs (enalapril, ramipril, perindopril), sacubitril, and clopidogrel, with the loss-of-function G143E variant markedly reducing catalytic efficiency in vitro and diminishing prodrug activation and pharmacodynamic response in vivo [PMID:18485328, PMID:26817948, PMID:26076923, PMID:33963573, PMID:36695375]. Beyond xenobiotic metabolism, CES1 redirects hepatic fatty acids from triacylglycerol synthesis toward β-oxidation, modulates VLDL secretion, hydrolyzes prostaglandin glyceryl esters in macrophages to regulate inflammation, and sustains a PUFA–PPARα/γ–SCD axis that promotes tumor lipid remodeling [PMID:29631096, PMID:33225149, PMID:36472914, PMID:29259301]. CES1 transcription is positively regulated by PXR and FXR and repressed by the G9a histone methyltransferase, while its expression is also induced through the NOX/ROS/Nrf2 pathway, and hepatic CES1 protein abundance increases approximately 5-fold from the neonatal period to adulthood [PMID:26340669, PMID:37042626, PMID:36695375, PMID:27895113].\",\n  \"teleology\": [\n    {\n      \"year\": 2008,\n      \"claim\": \"Establishing that CES1 is the principal hydrolase for methylphenidate and that specific coding variants (G143E, D260fs) quantitatively ablate catalytic function answered the foundational question of whether genetic variation could explain interindividual differences in prodrug metabolism.\",\n      \"evidence\": \"Recombinant wild-type and mutant CES1 kinetic assays (Vmax/Km) with p-nitrophenyl acetate and methylphenidate in transfected cell lines\",\n      \"pmids\": [\"18485328\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate scope beyond methylphenidate not yet explored\", \"No in vivo pharmacokinetic data for G143E carriers\", \"Structural basis for G143E loss of function not resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrating that CES1 selectively activates multiple ACE inhibitor prodrugs in human liver, and that G143E reduces enalapril activation to ~one-third, broadened the pharmacogenomic relevance of CES1 from a single drug to a major prodrug class.\",\n      \"evidence\": \"Human liver/intestine/kidney S9 fraction incubations with selective CES1 inhibitor; genotype-stratified activity in human liver samples; transfected cell lines with wild-type vs. G143E CES1\",\n      \"pmids\": [\"26076923\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo clinical PK/PD consequence not yet demonstrated at this point\", \"Whether other CES1 variants affect ACE inhibitor activation unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identifying PXR as a direct transcriptional activator of CES1 through reciprocal overexpression/knockdown experiments established the first nuclear receptor regulatory axis for CES1 gene expression.\",\n      \"evidence\": \"PXR overexpression and siRNA knockdown in HepG2 cells measuring CES1 mRNA and enzymatic activity; fluoxetine as a pharmacological perturbant\",\n      \"pmids\": [\"26340669\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"PXR binding to a CES1 promoter element not shown by ChIP\", \"Relevance in primary human hepatocytes not confirmed\", \"DEC1 repressive mechanism incompletely characterized\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showing that hepatic CES1 protein abundance increases ~5-fold from neonates to adults and correlates with oseltamivir carboxylase activity established a developmental basis for age-dependent prodrug metabolism.\",\n      \"evidence\": \"LC-MS/MS targeted proteomics of 136 pediatric and 35 adult human liver microsomes correlated with enzymatic activity\",\n      \"pmids\": [\"27895113\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcriptional vs. post-translational mechanisms underlying developmental increase not dissected\", \"Functional impact on neonatal drug dosing not directly tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrating selective CES1-mediated activation of sacubitril and impairment by G143E extended the pharmacogenomic impact of CES1 to cardiovascular prodrugs beyond ACE inhibitors.\",\n      \"evidence\": \"Human liver/intestine/kidney S9 fractions with CES1 inhibitor; recombinant CES1/CES2 assays; wild-type vs. G143E transfected cells\",\n      \"pmids\": [\"26817948\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo clinical impact of G143E on sacubitril PK not tested\", \"Whether CES1 abundance variation in liver influences sacubitril response unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Global Ces1g knockout in mice revealed an endogenous role for CES1 in intestinal cholesterol absorption (via NPC1L1) and macrophage cholesterol efflux (via ABCA1/ABCG1), linking CES1 to atherosclerosis pathophysiology beyond hepatic lipid handling.\",\n      \"evidence\": \"Ces1g−/− and Ces1g−/− Ldlr−/− mice on Western diet; atherosclerotic lesion quantification; macrophage cholesterol efflux and gene expression profiling\",\n      \"pmids\": [\"29259301\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mouse Ces1g is not identical to human CES1 — translatability uncertain\", \"Whether effects are cell-autonomous in macrophages vs. secondary to hepatic lipid changes not fully resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"A humanized mouse model expressing CES1 wild-type vs. G143E vs. catalytically dead S221A demonstrated that reduced CES1 catalytic activity paradoxically lowers hepatic/plasma TG by decreasing VLDL secretion and increasing fatty acid β-oxidation, resolving the directionality of CES1's role in hepatic lipid flux.\",\n      \"evidence\": \"Humanized mouse liver expression of CES1 variants on high-fat diet; VLDL secretion rates, plasma ketone bodies, mitochondrial ETC protein quantification\",\n      \"pmids\": [\"29631096\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How reduced esterase activity redirects FA toward β-oxidation mechanistically remains unclear\", \"Whether the same metabolic reprogramming occurs in human liver is unproven\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"CES1 was shown to hydrolyze prostaglandin glyceryl esters (PGD2-G, PGE2-G) in macrophages, accounting for ~50% of PGD2-G catabolism, establishing CES1 as a regulator of endocannabinoid-like lipid mediator tone and macrophage inflammatory signaling.\",\n      \"evidence\": \"CES1 pharmacological inhibitors and genetic knockdown in THP-1 macrophages; LC-MS/MS quantification of PG-G metabolites; IL-6/TNFα cytokine and PPARγ activation readouts\",\n      \"pmids\": [\"33225149\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of CES1 vs. other hydrolases to PG-G catabolism in primary human macrophages not established\", \"In vivo relevance for inflammatory disease not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"A prospective clinical PK/PD study confirmed that G143E carriers have ~28% lower enalaprilat exposure and lose the systolic blood pressure–lowering effect of enalapril, providing the first direct in vivo human evidence that CES1 genotype determines prodrug therapeutic efficacy.\",\n      \"evidence\": \"Multi-dose clinical study with LC-MS/MS quantification of enalapril/enalaprilat; genotype-stratified PK and blood-pressure endpoints\",\n      \"pmids\": [\"33963573\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Study size modest — replication in larger cohorts needed\", \"Whether dose adjustment can compensate for G143E not examined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"CES1 restoration by melatonin in prostate cancer cells reduced lipid droplet accumulation, induced ER stress–mediated apoptosis, and blocked intratumoral androgen synthesis, reversing enzalutamide resistance — linking CES1 lipid metabolism to castration-resistant prostate cancer biology.\",\n      \"evidence\": \"CRPC mouse models; Ces1−/− mice; PCa cell lines with CES1 expression restoration; lipid droplet, ER stress marker, and androgen synthesis measurements\",\n      \"pmids\": [\"34185414\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Epigenetic mechanism by which melatonin restores CES1 not fully defined\", \"Direct CES1 substrate responsible for lipid droplet reduction in PCa not identified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"TMAO was found to upregulate CES1 through a NOX/ROS/Nrf2 signaling axis, increasing clopidogrel hydrolysis and reducing its active metabolite — revealing an environmentally driven transcriptional circuit that modulates CES1-dependent drug metabolism.\",\n      \"evidence\": \"TMAO/choline-fed mice with clopidogrel PK and platelet aggregation; HepG2 cells with N-acetyl-L-cysteine, Nrf2 inhibitor ML385, and NOX inhibitor apocynin\",\n      \"pmids\": [\"36695375\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether Nrf2 directly binds CES1 promoter not shown by ChIP\", \"Relevance to clinical clopidogrel resistance in humans requires prospective validation\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrating that CES1 supplies PUFAs that activate PPARα/γ to drive SCD expression in hepatocellular carcinoma established a CES1–PUFA–PPARα/γ–SCD lipid signaling axis relevant to chemoresistance.\",\n      \"evidence\": \"Pharmacological and genetic CES1 inhibition in HCC cell lines; lipidomics; PPARα/γ activation assays; xenograft mouse model with cisplatin co-treatment\",\n      \"pmids\": [\"36472914\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific CES1 lipid substrates generating tumor-relevant PUFAs not identified\", \"Applicability beyond HCC not explored\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identification of G9a as an epigenetic repressor that competes with FXR at the Ces1 promoter revealed a chromatin-level regulatory switch controlling Ces1 expression and lipid accumulation in renal tubular cells.\",\n      \"evidence\": \"Renal tubular-specific G9a knockout mice; pharmacological G9a and Ces1 inhibition; promoter binding competition studies; ischemia-reperfusion and cisplatin AKI models\",\n      \"pmids\": [\"37042626\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether this G9a/FXR competition operates at the human CES1 promoter in liver not examined\", \"Histone mark (H3K9me2) dynamics at CES1 locus not fully mapped\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include the identity of endogenous lipid substrates responsible for CES1's metabolic effects in different tissues, the structural basis for G143E loss of function, whether CES1 pharmacogenomic findings translate to clinical dosing guidelines, and how CES1 transcriptional regulation is integrated across PXR, FXR, Nrf2, and G9a inputs in vivo.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal structure of human CES1 with G143E mutation available\", \"No clinical trials using CES1 genotype for dose adjustment\", \"Integration of multiple transcriptional regulators in a unified model not achieved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1, 2, 3, 5, 7, 10, 13]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [4, 5, 7, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [13]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [4, 5, 6, 7, 8, 9, 12]},\n      {\"term_id\": \"R-HSA-9748784\", \"supporting_discovery_ids\": [0, 1, 2, 3, 10, 13]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 10, 11]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"PXR\",\n      \"FXR\",\n      \"NRF2\",\n      \"G9A\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"Insufficient on-target evidence to synthesize a narrative — discovery timeline does not match the canonical CES1 protein.\",\n  \"teleology\": [],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [],\n    \"localization\": [],\n    \"pathway\": [],\n    \"complexes\": [],\n    \"partners\": [],\n    \"other_free_text\": []\n  }\n}\n```"}